Compare Monolithic Power Systems Inc (MPWR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs TG Therapeutics Inc — how do they compare? Monolithic Power Systems Inc trades at $1,424 (market cap $68.90B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Monolithic Power Systems Inc is far larger — about 9× TG Therapeutics Inc's market cap, and Monolithic Power Systems Inc pays a 0.57% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MPWR | TGTX | |
|---|---|---|
Market Cap | $68.90B | $7.64B |
Sector | Utilities | Health |
52-Week High | $1.69K | $59.06 |
52-Week Low | $820.74 | $26.94 |
Enterprise Value | $67.51B | $7.84B |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPWR trades at $1,425.01, up 3.18% in 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 24.5% net income margin and 21.98% ROE, supported by AI-driven revenue growth. Recent news highlights legal scrutiny but also analyst optimism post-Q2 results.
Outlook is positive with an 88% buy rating from analysts and a $1,870 consensus price target, though high valuation ratios and competitive risks warrant caution. Upside hinges on continued AI infrastructure demand, while downside risks include execution challenges and market volatility.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
